Galectin-3 in pre-B acute lymphoblastic leukemia

Abstract

Only 30-40% of adult patients with acute lymphoblastic leukemia (ALL) achieve long-term, disease-free survival and can be considered cured. The remainder will eventually relapse and die from disease progression or other ALL-related consequences. Relapse most frequently originates in the bone marrow (BM),3 where stroma protects ALL cells against drug treatment.